miR-1268a–CD36 Axis in Angiotensin II-Induced Heart Failure
2026-06-29
This study elucidates how miR-1268a regulates fatty acid metabolism by targeting CD36 in a human cardiomyocyte model of Angiotensin II-induced heart failure. The findings reveal that miR-1268a upregulation contributes to impaired cell energetics and increased oxidative stress, highlighting a novel regulatory axis relevant to cardiovascular remodeling and metabolic dysfunction.
EZ Cap Cy5 Firefly Luciferase mRNA: Next-Gen Dual Reporter f
2026-06-28
Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) revolutionizes real-time mRNA delivery and translation assays with dual-mode detection and advanced immunogenicity control. Discover protocol guidance, comparative insights, and foundational research that shape the future of mRNA-based biotechnology.
Trilaurin (Glycerol Tridodecanoate): Multifunctional Roles i
2026-06-27
Explore the multifaceted applications of Trilaurin (Glycerol Tridodecanoate) as a biocatalytic substrate, lipid excipient, and enabler of next-generation drug delivery. This article offers a deep technical analysis and practical insights beyond standard workflow guides.
Ferrostatin-1 in Ferroptosis Assays: Protocols, Pitfalls, an
2026-06-26
Ferrostatin-1 (Fer-1) is the gold standard for inhibiting ferroptosis, bringing precision and reproducibility to models of oxidative cell death. This article translates recent mechanistic insights into actionable experimental strategies, with a focus on troubleshooting and protocol refinement in cancer, neurodegeneration, and emerging ophthalmic models.
Pharmacokinetics of Temafloxacin: Implications for Antibacte
2026-06-26
The reference review provides a comprehensive analysis of the pharmacokinetic profile of temafloxacin, a new fluoroquinolone, highlighting its high oral bioavailability, extensive tissue distribution, and prolonged elimination half-life. These features inform dose optimization and regimen flexibility for antibacterial therapy, with direct implications for translational research and PK/PD modeling.
Drug-Sensitized Yeast System Enhances mTOR Inhibitor Discove
2026-06-25
The referenced study introduces a yeast-based screening platform with heightened sensitivity for identifying mTOR inhibitors by exploiting specific genetic backgrounds and drug efflux deletions. This innovation promises to accelerate the discovery of novel geroprotective and anti-cancer agents, while also providing valuable negative data for compounds such as Nebivolol hydrochloride.
Trichostatin A (TSA): Data-Driven Solutions for Cell Assays
2026-06-25
This scenario-driven guide addresses key experimental challenges in cell viability, proliferation, and cytotoxicity assays, showing how Trichostatin A (TSA, SKU A8183) from APExBIO delivers reproducible, literature-backed outcomes. Focused on practical optimization and robust epigenetic insights, it provides researchers with actionable, evidence-based strategies for integrating TSA into cancer and epigenetic research workflows.
Gepotidacin (GSK2140944): Protocols for Antibacterial Resear
2026-06-24
Gepotidacin (GSK2140944) stands out as a first-in-class DNA gyrase inhibitor, empowering researchers to tackle antibiotic resistance with precision. This article delivers practical workflows, protocol parameters, and troubleshooting insights to unlock Gepotidacin’s full potential in advanced antibacterial research.
Eltanexor (KPT-8602): Optimizing Nuclear Export Inhibition i
2026-06-23
Eltanexor (KPT-8602) empowers translational oncology with its potent, second-generation inhibition of XPO1-mediated nuclear export and exceptional tolerability across hematologic and solid tumor models. Explore stepwise protocols, experiment-driven troubleshooting, and the latest cross-cancer insights for deploying this oral bioavailable XPO1 inhibitor in advanced research applications.
Recombinant Human EGF: Mechanisms, Synthetic Lethality, and
2026-06-23
Explore the multifaceted roles of recombinant human Epidermal Growth Factor (EGF) in cell signaling, synthetic lethality, and translational research. This article uniquely integrates mechanistic depth, practical protocol advice, and novel insights from recent chemogenetic screens, offering a comprehensive resource for advanced cell biology and oncology studies.
Continuous Rotigotine Delivery in PD and RLS: Study Insights
2026-06-22
This review details the innovation and clinical validation of continuous rotigotine transdermal delivery for Parkinson’s disease and restless legs syndrome. The study highlights how sustained dopaminergic stimulation via a non-ergoline dopamine D2/D3 receptor agonist improves both motor and non-motor symptoms, addressing limitations of short-acting oral therapies.
WY-14643 (Pirinixic Acid): Precision Tool for Metabolic Rese
2026-06-22
WY-14643 (Pirinixic Acid) offers unmatched selectivity and potency for dissecting PPARα-driven metabolic and inflammatory pathways in preclinical models. This article explores optimized workflows, troubleshooting guidance, and key innovations in liver regeneration research leveraging APExBIO’s trusted compound.
Melittin: Bioactive Peptide Workflows in Cancer Biology Rese
2026-06-21
Melittin empowers researchers to modulate cell signaling pathways with precision, uniquely enabling advanced signal transduction and apoptosis research. This guide translates the latest glioblastoma findings into actionable workflows and troubleshooting strategies for maximizing the peptide's utility in cancer biology.
Cy5.5 NHS Ester (Non-Sulfonated): Optimizing In Vivo Imaging
2026-06-20
Cy5.5 NHS ester (non-sulfonated) stands out as a gold-standard near-infrared dye for protein and nanoparticle labeling, enabling deep-tissue, high-precision optical imaging. This guide details best practices, protocol optimizations, and troubleshooting for applying Cy5.5 NHS ester to advanced workflows such as blood-brain barrier-crossing nanoparticle tracking and tumor visualization.
Regorafenib Suppresses Melanoma via RRM2 and ERK/E2F3 Downre
2026-06-19
A recent study demonstrates that Regorafenib (BAY 73-4506) inhibits melanoma progression by downregulating RRM2 and disrupting ERK/E2F3 signaling, leading to reduced proliferation and increased apoptosis in melanoma cells. These findings refine the mechanistic understanding of Regorafenib’s antitumor action and offer new directions for targeted melanoma research.
479 records 15/32 page Previous Next First page 上5页 1112131415 下5页 Last page